secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001437749-25-020040
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Phase 1 norovirus vaccine data: 141% (GI.1) and 94% (GII.4) antibody titer increases vs first-gen
--------------------------------------------------------------------------------

- Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.
- All constructs safe and well-tolerated; no vaccine-related serious adverse events reported.
- Vaxart plans Phase 2b as early as H2 2025, Phase 3 potentially in 2026, pending partnership/funding.
- Company believes data supports potential for first-in-class or best-in-class oral norovirus vaccine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/0001437749-25-020040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/vxrt20250611_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-020040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer